Finance

Lists
2096:HKG
Simcere Pharmaceutical Group Ltd
HK$ 11.02
+1.75%
(+0.19) 1D
10-р сарын 16, 16:08:14 (GMT+8)  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 2096...
Open
HK$ 10.85
High
HK$ 11.29
Low
HK$ 10.85
Mkt. cap
28.30 тэрбум
Avg. vol.
4.02 сая
Volume
5.80 сая
Dividend
1.88%
Quarterly dividend
HK$ 0.05
Ex-dividend date
2025 оны 6-р сарын 18
P/E ratio
16.54
52-wk high
HK$ 14.38
52-wk low
HK$ 9.07
EPS
HK$ 0.67
Shares outstanding
2.57 тэрбум
No. of employees
7 мян
Open
HK$ 10.85
High
HK$ 11.29
Low
HK$ 10.85
Mkt. cap
28.30 тэрбум
Avg. vol.
4.02 сая
Volume
5.80 сая
Dividend
1.88%
Quarterly dividend
HK$ 0.05
Ex-dividend date
2025 оны 6-р сарын 18
P/E ratio
16.54
52-wk high
HK$ 14.38
52-wk low
HK$ 9.07
EPS
HK$ 0.67
Shares outstanding
2.57 тэрбум
No. of employees
7 мян
News stories
From web sources and news partners
Profile
Simcere Pharmaceutical Group or Simcere Pharmaceutical is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. Its focus is to introduce generic and pharmaceutical products for the treatment of diseases with high incidence and/or mortality rate. The company has introduced a generic anti-stroke medication under the brand name, Bicun, and an anti-cancer medication under the brand name, Endu. Its products include antibiotics, anti-stroke medications, anti-inflammatory drugs, anti-cancer medications and other medicines. In addition, it has obtained approvals from the China State Food and Drug Administration to manufacture and sell over 210 other products. Wikipedia
About Simcere Pharmaceutical Group Ltd
CEORen Jinsheng
Employees7.06 мян
Founded1995
HeadquartersNanjing, Jiangsu, Хятад
SectorPharmaceutical industry
Previous reports
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
2.07 тэрбум
2.07 тэрбум
2.29 тэрбум
2.29 тэрбум
Cost of goods sold
365.25 сая
365.25 сая
382.55 сая
382.55 сая
Cost of revenue
365.25 сая
365.25 сая
382.55 сая
382.55 сая
Research and development expenses
465.30 сая
465.30 сая
412.46 сая
412.46 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
949.52 сая
949.52 сая
1.01 тэрбум
1.01 тэрбум
Operating expense
1.36 тэрбум
1.36 тэрбум
1.39 тэрбум
1.39 тэрбум
Total operating expenses
1.72 тэрбум
1.72 тэрбум
1.77 тэрбум
1.77 тэрбум
Operating income
351.33 сая
351.33 сая
520.99 сая
520.99 сая
Other non operating income
-
-
-
-
EBT including unusual items
425.92 сая
425.92 сая
483.36 сая
483.36 сая
EBT excluding unusual items
348.89 сая
348.89 сая
531.61 сая
531.61 сая
Income tax expense
55.72 сая
55.72 сая
70.09 сая
70.09 сая
Effective tax rate
13.08%
13.08%
14.50%
14.50%
Other operating expenses
-56.27 сая
-56.27 сая
-42.94 сая
-42.94 сая
Net income
370.20 сая
370.20 сая
414.36 сая
414.36 сая
Net profit margin
17.86%
17.86%
18.09%
18.09%
Earnings per share
-
-
-
-
Interest and investment income
14.60 сая
14.60 сая
24.20 сая
24.20 сая
Interest expense
-23.63 сая
-23.63 сая
-24.61 сая
-24.61 сая
Net interest expenses
-9.03 сая
-9.03 сая
-416.00 мян
-416.00 мян
Depreciation and amortization charges
-
-
-
-
EBITDA
449.72 сая
449.72 сая
606.04 сая
606.04 сая
Gain or loss from assets sale
-115.50 мян
-115.50 мян
-
-
AI content may include mistakes. Learn more
Google аппс